Oculis Holding AG (OCS)
NASDAQ: OCS · Real-Time Price · USD
27.56
+0.44 (1.62%)
Apr 14, 2026, 4:00 PM EDT - Market closed
Oculis Holding AG Revenue
In the year 2025, Oculis Holding AG had annual revenue of 1.20M CHF with 74.78% growth. Oculis Holding AG had revenue of 411.00K in the quarter ending December 31, 2025, with 13,600.00% growth.
Revenue (ttm)
1.20M CHF
Revenue Growth
+74.78%
P/S Ratio
1,082.76
Revenue / Employee
24,469 CHF
Employees
49
Market Cap
1.63B USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.20M | 513.00K | 74.78% |
| Dec 31, 2024 | 686.00K | -197.00K | -22.31% |
| Dec 31, 2023 | 883.00K | -29.00K | -3.18% |
| Dec 31, 2022 | 912.00K | -48.00K | -5.00% |
| Dec 31, 2021 | 960.00K | -33.00K | -3.32% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 868.45M |
| Immunocore Holdings | 400.02M |
| Iovance Biotherapeutics | 263.50M |
| Nurix Therapeutics | 71.78M |
| Viridian Therapeutics | 70.85M |
| Intellia Therapeutics | 67.67M |
| Nuvation Bio | 62.90M |
OCS News
- 5 days ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - GlobeNewsWire
- 7 days ago - Oculis to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 14 days ago - Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis - GlobeNewsWire
- 4 weeks ago - Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting - GlobeNewsWire
- 5 weeks ago - Oculis Publishes 2025 Consolidated Financial Statements - GlobeNewsWire
- 5 weeks ago - Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update - GlobeNewsWire
- 7 weeks ago - Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated - GlobeNewsWire
- 2 months ago - Oculis Appoints Katie Kazem as Chief Legal Officer - GlobeNewsWire